• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • TBK1 Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • Adenosine Kinase Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

ENPP1 Inhibitors, Assays, and Innate Immunity

by Bellbrook Labs / Wednesday, 16 October 2019 / Published in Emerging Targets
ENPP1 Inhibitors Improve Innate Immunity

The human immune response is incredible. Unlike the adaptive immune response, the innate response acts quickly and is considered the first line of defense against pathogens and foreign DNA such as tumor cells. To be effective, the innate immune response relies on several cell types and a multitude of proteins such as interferons (INFs). This group of cytokines consists of three types and facilitates the removal of viral pathogens. Activation of interferon regulatory factor 3 (IRF3) leads to type I interferon production, which typically fights microbial infection-causing pathogens.¹ Immunotherapy has become an effective and well-liked means to treat cancer. Numerous drugs are on the market using this strategy. And, researchers are constantly discovering more proteins and pathways with the potential to treat cancer through immunotherapy.

The Ectonucleotide Capacity of ENPP1

Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) is an enzyme that breaks down nucleotides to nucleosides. Additionally, it is responsible for metabolizes 2’3’-cGAMP into its corresponding nucleotide (AMP and GMP) by degrading phosphodiester bonds.² The cyclic di-nucleotide is formed in response to double-stranded DNA (dsDNA) in the cytosol of a host cell, alerting the innate immune system to dangerous intracellular pathogens and damaged or cancerous cells.¹

ENPP1 Regulates STING pathway

Experts believe the STING pathway is the main innate immune sensing pathway within the tumor microenvironment and have found that STING is even epigenetically silenced in some cancers.² The STING (stimulator of interferon genes) pathway ultimately leads to the phosphorylation and activation of IRF3; therefore, initiating antiviral activity. ENPP1 regulates this process by degrading 2’3’-cGAMP, inhibiting the binding to STING, which impedes the successive steps to IRF3 activation.²  Stalling ENPP1 might be a great approach to stimulate the innate response by means of keeping the STING pathway open for business so to speak.

Takeaways

The therapeutic potential in ENPP1 is vast. One area is breast cancer since ENPP1 has been found to be highly expressed in some breast cancers and its level has been correlated with poor prognosis.¹ As is the case with most proteins with biological function, there are some considerable hurdles scientists will face before finding the ideal drug though. Although analogs of 2’3’-cGAMP are resistant to ENPP1, the multiple distinct functions of the enzyme cause development challenges for specificity.²

ENPP1 Inhibitors Could Be An Option

Finding ENPP1 inhibitors that functionally stop the degradation of cGAMP could effectively be the avenue of choice. Biochemical activity assays provide a tool to sift through vast compound libraries on a quest for a molecule with the best properties. The Transceener AMP/GMP Assay could provide one possibility. The assay can readily measure the AMP or GMP produced when ENPP1 degrades cGAMP, effectively determining its enzymatic ability in the presence of various compounds. As a simple mix-and-read assay system, Transcreener provides a simple yet powerful method that is HTS compatible and a proven fit for hit-to-lead discovery.

Learn More About the Assay

References

1. Jacqueline A Carozza, et al. 2’3′-cGAMP is an immunotransmitter produced by cancer cells and regulated by ENPP1. bioRxiv 539312; doi: https://doi.org/10.1101/539312
2. Kaadige MR. Development of Enpp1 Inhibitors as a Strategy to Activate Stimulator of Interferon Genes (STING) in Cancers and Other Diseases. Int J Cell Sci Mol Biol. 2018;5(1):1-5. doi:10.19080/ijcsmb.2018.05.555655

Tagged under: ENPP1 Assay, Transcreener AMP/GMP Assay

What you can read next

Unraveling RhoGDIα Regulation
Sphingosine Kinase Shows Promise as New Target for Viral Lymphomas
Helicases as Drug Discovery Targets

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Scientist Studying ALKPK1

    The Role ALPK1 in Health and Disease

    ALPK1 (Alpha Kinase 1) is an atypical serine/th...
  • DHX36 RNA Helicase Unwinds G4 RNA Structures

    Resolving the Many Roles of DHX36

    While most researchers are familiar with canoni...
  • Researcher Studying MAPK14

    MAPK14 in Context

    MAPK14 (or p38 alpha or SAPK2a) is a proline-di...
  • PRMT5 Role with Macrophages

    PRMT5 is Innately Interesting

    PRMT5 is a type II arginine methyltransferase t...
  • IRE1 Proteins in ER

    The Multifaceted Roles of IRE1 Are Unfolding

    IRE1 (Inositol-Requiring Enzyme 1) is one of th...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2021 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP